Prucalopride
Prucalopride is a 5-HT4 receptor agonist approved for the treatment of constipation in adults.[53]van Mill MJ, Koppen IJN, Benninga MA. Controversies in the management of functional constipation in children. Curr Gastroenterol Rep. 2019 Apr 25;21(6):23.
https://link.springer.com/article/10.1007/s11894-019-0690-9
http://www.ncbi.nlm.nih.gov/pubmed/31025225?tool=bestpractice.com
5-HT4 is a serotonin receptor with a role in gastrointestinal motility. Enhancing the activity of 5-HT4 with receptor agonists has been shown to improve functional constipation.[54]Hoffman JM, Tyler K, MacEachern SJ, et al. Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology. 2012 Apr;142(4):844-54.e4.
https://www.gastrojournal.org/article/S0016-5085(12)00003-0/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/22226658?tool=bestpractice.com
The results of a multicentre, randomised, placebo-controlled, double-blind phase III trial to evaluate the efficacy and safety of prucalopride in children aged 6 months to 18 years with functional constipation found that although the drug was generally well tolerated, it was no more effective than placebo.[55]Mugie SM, Korczowski B, Bodi P, et al. Prucalopride is no more effective than placebo for children with functional constipation. Gastroenterology. 2014 Dec;147(6):1285-95.e1.
https://www.gastrojournal.org/article/S0016-5085%2814%2901127-5/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/25239590?tool=bestpractice.com
Other trials of prucalopride in children and adolescents remain ongoing.
Lubiprostone
Lubiprostone is an oral chloride channel activator that enhances gastrointestinal fluid secretion, subsequently softening stools and facilitating bowel movements. It has been approved for use in adult patients in the US since 2006. Clinical trials in children have shown that lubiprostone has a similar safety profile to that observed in adults, but efficacy results have been mixed.[56]Hussain SZ, Labrum B, Mareya S, et al. Safety of lubiprostone in pediatric patients with functional constipation: a nonrandomized, open-label Trial. J Pediatr Gastroenterol Nutr. 2021 Nov 1;73(5):572-8.
https://journals.lww.com/jpgn/Fulltext/2021/11000/Safety_of_Lubiprostone_in_Pediatric_Patients_With.2.aspx
http://www.ncbi.nlm.nih.gov/pubmed/34387619?tool=bestpractice.com
[57]Hyman PE, Di Lorenzo C, Prestridge LL, et al. Lubiprostone for the treatment of functional constipation in children. J Pediatr Gastroenterol Nutr. 2014 Mar;58(3):283-91.
https://journals.lww.com/jpgn/Fulltext/2014/03000/Lubiprostone_for_the_Treatment_of_Functional.5.aspx
http://www.ncbi.nlm.nih.gov/pubmed/24048162?tool=bestpractice.com
[58]Benninga MA, Hussain SZ, Sood MR, et al. Lubiprostone for pediatric functional constipation: randomized, controlled, double-blind study with long-term extension. Clin Gastroenterol Hepatol. 2022 Mar;20(3):602-10.e5.
https://www.cghjournal.org/article/S1542-3565(21)00393-1/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/33838349?tool=bestpractice.com
In one open-label study that enrolled 127 children aged ≤17 years, lubiprostone significantly improved spontaneous bowel movements (SBM) from baseline to week 4.[57]Hyman PE, Di Lorenzo C, Prestridge LL, et al. Lubiprostone for the treatment of functional constipation in children. J Pediatr Gastroenterol Nutr. 2014 Mar;58(3):283-91.
https://journals.lww.com/jpgn/Fulltext/2014/03000/Lubiprostone_for_the_Treatment_of_Functional.5.aspx
http://www.ncbi.nlm.nih.gov/pubmed/24048162?tool=bestpractice.com
However, in a phase 3 randomised controlled trial, lubiprostone failed to significantly improve SBM compared to placebo from baseline to week 12.[58]Benninga MA, Hussain SZ, Sood MR, et al. Lubiprostone for pediatric functional constipation: randomized, controlled, double-blind study with long-term extension. Clin Gastroenterol Hepatol. 2022 Mar;20(3):602-10.e5.
https://www.cghjournal.org/article/S1542-3565(21)00393-1/fulltext
http://www.ncbi.nlm.nih.gov/pubmed/33838349?tool=bestpractice.com
Lubiprostone continues to be used off-label in children in some centres.
Botulinum toxin
Injection of botulinum toxin type A into the intra-anal sphincter shows some promising response, and several groups are using this therapy, especially when anal fissures are present, or a hypertonic or non-normally relaxing internal anal sphincter is present.[59]Halleran DR, Lu PL, Ahmad H, et al. Anal sphincter botulinum toxin injection in children with functional anorectal and colonic disorders: a large institutional study and review of the literature focusing on complications. J Pediatr Surg. 2019 Nov;54(11):2305-10.
http://www.ncbi.nlm.nih.gov/pubmed/31060739?tool=bestpractice.com
[60]Zar-Kessler C, Kuo B, Belkind-Gerson J. Botulinum toxin injection for childhood constipation is safe and can be effective regardless of anal sphincter dynamics. J Pediatr Surg. 2018 Apr;53(4):693-7.
http://www.ncbi.nlm.nih.gov/pubmed/29395154?tool=bestpractice.com
Limitations include cost, requirement for general anaesthetic, and transient efficacy.[53]van Mill MJ, Koppen IJN, Benninga MA. Controversies in the management of functional constipation in children. Curr Gastroenterol Rep. 2019 Apr 25;21(6):23.
https://link.springer.com/article/10.1007/s11894-019-0690-9
http://www.ncbi.nlm.nih.gov/pubmed/31025225?tool=bestpractice.com
Probiotics
It is hypothesised that probiotics favourably alter the gut microbiome and promote normal gut physiology in a way that leads to improvement in constipation. However, their use remains controversial.[30]Paul SP, Broad SR, Spray C. Idiopathic constipation in children clinical practice guidelines. Arch Dis Child Educ Pract Ed. 2016 Apr;101(2):65-9.
http://www.ncbi.nlm.nih.gov/pubmed/26276787?tool=bestpractice.com
[53]van Mill MJ, Koppen IJN, Benninga MA. Controversies in the management of functional constipation in children. Curr Gastroenterol Rep. 2019 Apr 25;21(6):23.
https://link.springer.com/article/10.1007/s11894-019-0690-9
http://www.ncbi.nlm.nih.gov/pubmed/31025225?tool=bestpractice.com
One Cochrane review investigated the efficacy and safety of probiotics for the treatment of chronic functional constipation in children. The authors of the review concluded that there was a lack of evidence in the 14 evaluated studies to routinely recommend probiotics for this purpose.[61]Wallace C, Sinopoulou V, Gordon M, et al. Probiotics for treatment of chronic constipation in children. Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD014257.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014257.pub2/full
http://www.ncbi.nlm.nih.gov/pubmed/35349168?tool=bestpractice.com
Sacral nerve stimulation (SNS)
SNS involves implantation of an electrode in the sacral foramen in order to apply low-amplitude electrical stimulation to the sacral nerve.[53]van Mill MJ, Koppen IJN, Benninga MA. Controversies in the management of functional constipation in children. Curr Gastroenterol Rep. 2019 Apr 25;21(6):23.
https://link.springer.com/article/10.1007/s11894-019-0690-9
http://www.ncbi.nlm.nih.gov/pubmed/31025225?tool=bestpractice.com
Studies in children and adolescents have yielded mixed results, with some suggesting sustained results up to 2 years and other failing to show clinical benefit.[53]van Mill MJ, Koppen IJN, Benninga MA. Controversies in the management of functional constipation in children. Curr Gastroenterol Rep. 2019 Apr 25;21(6):23.
https://link.springer.com/article/10.1007/s11894-019-0690-9
http://www.ncbi.nlm.nih.gov/pubmed/31025225?tool=bestpractice.com
[62]Lu ML, He J, Lu S. Electrical stimulation therapy for slow transit constipation in children: a systematic review. Int J Colorectal Dis. 2015 May;30(5):697-702.
http://www.ncbi.nlm.nih.gov/pubmed/25772272?tool=bestpractice.com
[63]Sulkowski JP, Nacion KM, Deans KJ, et al. Sacral nerve stimulation: a promising therapy for fecal and urinary incontinence and constipation in children. J Pediatr Surg. 2015 Oct;50(10):1644-7.
http://www.ncbi.nlm.nih.gov/pubmed/25858097?tool=bestpractice.com
A non-invasive form of SNS has been piloted in a small group of 17 children (mean age 6.5 years) with promising results.[64]Besendörfer M, Kohl M, Schellerer V, et al. A pilot study of non-invasive sacral nerve stimulation in treatment of constipation in childhood and adolescence. Front Pediatr. 2020;8:169.
https://www.frontiersin.org/articles/10.3389/fped.2020.00169/full
http://www.ncbi.nlm.nih.gov/pubmed/32373563?tool=bestpractice.com
It is hoped that non-invasive SNS will avoid problems associated with electrode displacement as children grow.[64]Besendörfer M, Kohl M, Schellerer V, et al. A pilot study of non-invasive sacral nerve stimulation in treatment of constipation in childhood and adolescence. Front Pediatr. 2020;8:169.
https://www.frontiersin.org/articles/10.3389/fped.2020.00169/full
http://www.ncbi.nlm.nih.gov/pubmed/32373563?tool=bestpractice.com